Literature DB >> 32679088

Challenges and issues of SARS-CoV-2 pool testing.

Jens N Eberhardt1, Nikolas P Breuckmann2, Christiane S Eberhardt3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32679088      PMCID: PMC7832072          DOI: 10.1016/S1473-3099(20)30467-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   71.421


× No keyword cloud information.
We read with interest the Correspondence by Stefan Lohse and colleagues, who evaluated the practicability of pool testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pooling of samples yields considerable savings of test kits when the prevalence of infection is low because pools with all-negative samples can be discarded with a single test. Lohse and colleagues' findings suggest that pooling up to 30 samples is technically feasible with currently used and commercially available SARS-CoV-2 RT-PCR kits. But is bigger always better? Is it really efficient to pool 30 samples? First discussed around 80 years ago by Dorfman in the context of large-scale syphilis testing, the matter is complex and optimal pool sizes depend on the prevalence of infection in the population. Furthermore, there are more sophisticated pooling schemes than the one originally discussed by Dorfman, which use multiple stages of pooling or test samples in rows and columns of a matrix. We propose an adaptive approach that uses different pooling schemes depending on the estimated prevalence in a population. Our exhaustive comparison of testing schemes shows that three different schemes with initial pool sizes of 16, nine, and three samples are optimal for a prevalence of up to 3·5%, 3·5–12%, and 12–30%, respectively (appendix). The first two schemes are three-staged, meaning that if a pool tests positive it is further divided into sub-pools of four or three samples, before then testing samples individually. These schemes have a consistently higher testing efficiency than the method proposed by Lohse and colleagues, who used a three-staged scheme with initial pools of 30 samples and sub-pools of ten samples (appendix). For a prevalence of 2%, as in the population tested by Lohse and colleagues, our proposed testing scheme (pool size of 16 and four sub-pools of four samples) uses around 20% fewer tests. At higher prevalence, differences become even more pronounced and smaller pool sizes are optimal. For prevalence over 18%, pools of 30 samples are even less efficient than individual testing, whereas small pool sizes of three samples still yield a considerable improvement in efficiency (appendix). Hence bigger is not always better. Rather, it is preferable to choose one of the three proposed testing schemes based on the estimated underlying prevalence.
  3 in total

1.  The use of a square array scheme in blood testing.

Authors:  R M Phatarfod; A Sudbury
Journal:  Stat Med       Date:  1994-11-30       Impact factor: 2.373

2.  Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening.

Authors:  J N Eberhardt; N P Breuckmann; C S Eberhardt
Journal:  J Clin Virol       Date:  2020-04-23       Impact factor: 3.168

3.  Pooling of samples for testing for SARS-CoV-2 in asymptomatic people.

Authors:  Stefan Lohse; Thorsten Pfuhl; Barbara Berkó-Göttel; Jürgen Rissland; Tobias Geißler; Barbara Gärtner; Sören L Becker; Sophie Schneitler; Sigrun Smola
Journal:  Lancet Infect Dis       Date:  2020-04-28       Impact factor: 71.421

  3 in total
  5 in total

1.  A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers.

Authors:  Fabrice Bureau; Laurent Gillet; Claude Saegerman; Anh Nguyet Diep; Véronique Renault; Anne-Françoise Donneau; Lambert Stamatakis; Wouter Coppieters; Fabienne Michel; Christophe Breuer; Margaux Dandoy; Olivier Ek; Claire Gourzones; Joey Schyns; Emeline Goffin; Frédéric Minner; Keith Durkin; Maria Artesi; Vincent Bours
Journal:  Commun Med (Lond)       Date:  2022-01-10

2.  Safe and effective pool testing for SARS-CoV-2 detection.

Authors:  Marie Wunsch; Dominik Aschemeier; Eva Heger; Denise Ehrentraut; Jan Krüger; Martin Hufbauer; Adnan S Syed; Gibran Horemheb-Rubio; Felix Dewald; Irina Fish; Maike Schlotz; Henning Gruell; Max Augustin; Clara Lehmann; Rolf Kaiser; Elena Knops; Steffi Silling; Florian Klein
Journal:  J Clin Virol       Date:  2021-10-28       Impact factor: 3.168

3.  Monitoring for COVID-19 by universal testing in a homeless shelter in Germany: a prospective feasibility cohort study.

Authors:  Andreas K Lindner; Navina Sarma; Luise Marie Rust; Theresa Hellmund; Svetlana Krasovski-Nikiforovs; Mia Wintel; Sarah M Klaes; Merle Hoerig; Sophia Monert; Rolf Schwarzer; Anke Edelmann; Gabriela Equihua Martinez; Frank P Mockenhaupt; Tobias Kurth; Joachim Seybold
Journal:  BMC Infect Dis       Date:  2021-12-11       Impact factor: 3.090

4.  Clinical and epidemiological aspects of SARS-CoV-2 infection among pregnant and postpartum women in Mozambique: a prospective cohort study.

Authors:  Charles M'poca Charles; Nafissa Bique Osman; Domingos Arijama; Benjamim Matingane; Tomás Sitoé; Darlene Kenga; Cesaltina Lorenzoni; Elvira Luís; Rodolfo de Carvalho Pacagnella; Jahit Sacarlal
Journal:  Reprod Health       Date:  2022-07-19       Impact factor: 3.355

5.  Repetitive saliva-based mass screening as a tool for controlling SARS-CoV-2 transmission in nursing homes.

Authors:  Claude Saegerman; Anne-Françoise Donneau; Niko Speybroeck; Anh Nguyet Diep; Alexandria Williams; Lambert Stamatakis; Wouter Coppieters; Fabienne Michel; Christophe Breuer; Margaux Dandoy; Olivier Ek; Claire Gourzones; Joey Schyns; Emeline Goffin; Frédéric Minner; Véronique Renault; Laurent Gillet; Fabrice Bureau
Journal:  Transbound Emerg Dis       Date:  2021-08-17       Impact factor: 4.521

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.